Dr Reddys Laboratories (RDY) Debt to Equity (2022 - 2026)
Dr Reddys Laboratories has reported Debt to Equity over the past 5 years, most recently at $0.03 for Q1 2026.
- For Q1 2026, Debt to Equity fell 76.44% year-over-year to $0.03; the TTM value through Mar 2026 reached $0.03, down 76.44%, while the annual FY2026 figure was $0.03, 22.73% up from the prior year.
- Debt to Equity for Q1 2026 was $0.03 at Dr Reddys Laboratories, down from $0.14 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.17 in Q1 2022 and troughed at $0.03 in Q1 2024.
- A 5-year average of $0.08 and a median of $0.04 in 2023 define the central range for Debt to Equity.
- Biggest five-year swings in Debt to Equity: tumbled 78.22% in 2023 and later surged 423.5% in 2025.
- Year by year, Debt to Equity stood at $0.17 in 2022, then tumbled by 78.22% to $0.04 in 2023, then plummeted by 30.69% to $0.03 in 2024, then surged by 423.5% to $0.14 in 2025, then plummeted by 76.44% to $0.03 in 2026.
- Business Quant data shows Debt to Equity for RDY at $0.03 in Q1 2026, $0.14 in Q1 2025, and $0.03 in Q1 2024.